FDA Preemption Deadlocks Supreme Court; Congress Pushes To Resolve Issue
Executive Summary
Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval
You may also be interested in...
GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel
Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus
GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel
Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus
Public Citizen Litigation Group: Industry’s Relentless Adversary
Public Citizen Litigation Group has had plenty to cheer about this year. It argued four cases before the U.S. Supreme Court, winning three of them. Its one loss was particularly disappointing, though